Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan H Moy

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Cell|June 27, 2025
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesisJin Qian, Chenkai Ma, Quin T Waterbury, et al.
The Oncologist|October 2, 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric CancerRyan H Moy, Gustavo Dos Santos Fernandes, Philip Jonsson, et al.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Cell|June 27, 2025
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesisJin Qian, Chenkai Ma, Quin T Waterbury, et al.
The Oncologist|October 2, 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric CancerRyan H Moy, Gustavo Dos Santos Fernandes, Philip Jonsson, et al.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Pageof 4